CJC-1295 and ipamorelin are usually discussed as a pair, and the reason is mechanical, not marketing. One nudges the signal that starts the growth-hormone cascade; the other prompts a pulse of release. Here is how the pair is described in the research, why IGF-1 is the marker that matters, and where the evidence is honestly limited.
How the GH-axis pair signals · growth hormone peptides
CJC-1295 is a GHRH analog, meaning it is built to resemble growth-hormone-releasing hormone, the body’s own upstream signal. Ipamorelin is a GH secretagogue, a compound studied for its ability to prompt the pituitary to release a pulse of growth hormone. Paired, the idea explored in research is that one supports the underlying signal while the other encourages the release that follows.
The framing that matters: these peptides are studied for how they may influence the body’s own GH signaling, not for delivering growth hormone from outside. That is a meaningful distinction in both how they are described and how a physician would think about them. As with peptides generally, the popularity runs ahead of the evidence, which is covered more fully in peptides, by the evidence.
Why IGF-1 is the marker your physician checks · igf-1 marker
Growth hormone itself is hard to measure usefully, because it is released in short pulses and swings throughout the day. IGF-1, insulin-like growth factor 1, is the more stable downstream marker. The GH axis drives IGF-1 production, and IGF-1 stays steadier in the blood, so it gives a physician a more readable picture of what the axis is actually doing over time.
This is why IGF-1 sits on a comprehensive panel. It is the marker that puts any conversation about GH-axis peptides on measured footing rather than on how someone feels in a given week. A result is read against the reference range and, more importantly, against the rest of your markers and your own baseline. Marker first, molecule second.
you are
Add what fits. A physician reviews every order and arranges your consult and labs at checkout. Browse the shop →
Tesamorelin, a related GHRH analog
You may also see tesamorelin in the same category. It is another GHRH analog, so it works on the same upstream part of the axis as CJC-1295. Tesamorelin has its own regulatory and research history that differs from the CJC-1295 and ipamorelin pair, and a physician would weigh each separately rather than treating them as interchangeable. Grouping them by mechanism is useful for understanding; it does not mean the evidence or the appropriate use is the same.
What the evidence supports, and what your physician weighs
The honest evidence position is that CJC-1295 and ipamorelin are studied for their effect on GH-axis signaling, with human evidence that remains limited, and they are not FDA-approved drugs. When offered through a telehealth program they are physician-prescribed and prepared by a licensed compounding pharmacy under 503A or 503B rules, the federal frameworks for compounded medications. That structure makes the source traceable and keeps a qualified person in the loop. It does not turn early evidence into strong evidence.
What a physician weighs is the full picture, which is where the measurement step comes in. This is the “labs before molecules” idea: a baseline panel, including IGF-1 alongside your hormone and metabolic markers, gives a licensed physician the context to judge whether anything is appropriate or whether something else should be addressed first. It is also the baseline you measure response against later. The Telos approach begins with a core hormone and health panel, reviewed by a licensed physician through the affiliated medical group, who decides what, if anything, fits. Telos itself is a marketing and advertising company and does not practice medicine, prescribe, or dispense. Nothing here is medical advice.
